Mark A Pierce

Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.

M. Fay, C. Long, L. Miller, 2010, Vaccine.

Anti-Apical-Membrane-Antigen-1 Antibody Is More Effective than Anti-42-Kilodalton-Merozoite-Surface-Protein-1 Antibody in Inhibiting Plasmodium falciparum Growth, as Determined by the In Vitro Growth Inhibition Assay

M. Fay, Hong Zhou, C. Long, 2009, Clinical and Vaccine Immunology.

A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults.

A. Dicko, O. Doumbo, M. Fay, 2009, Vaccine.

A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali.

A. Dicko, O. Doumbo, M. Fay, 2009, Vaccine.

Phase 1 Study of a Combination AMA1 Blood Stage Malaria Vaccine in Malian Children

A. Dicko, O. Doumbo, M. Fay, 2008, PloS one.

A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals.

M. Fay, A. Saul, C. Long, 2009, Vaccine.

A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali.

A. Dicko, O. Doumbo, M. Fay, 2009, Vaccine.